PT  - JOURNAL ARTICLE
ED  - ,
TI  - Risk of serious adverse effects with Janus kinase inhibitors
AID  - 10.1136/dtb.2022.000078
DP  - 2023 Mar 01
TA  - Drug and Therapeutics Bulletin
PG  - 35--35
VI  - 61
IP  - 3
4099  - http://dtb.bmj.com/content/61/3/35.short
4100  - http://dtb.bmj.com/content/61/3/35.full
SO  - Drug Ther Bull2023 Mar 01; 61
AB  - Overview of: European Medicines Agency. EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders. November 2022.